EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 38 / Numéro 1 (Janvier 2022) Med Sci (Paris), 38 1 (2022) 45-51 Références
Open Access
Numéro
Med Sci (Paris)
Volume 38, Numéro 1, Janvier 2022
Page(s) 45 - 51
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2021241
Publié en ligne 21 janvier 2022
  1. Jellinger KA. Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) 2009 ; 116 : 1111–1162. [CrossRef] [PubMed] [Google Scholar]
  2. Sakamoto M, Uchihara T, Hayashi M, et al. Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for alpha-synuclein, ubiquitin, and thiazin red. Exp Neurol 2002 ; 177 : 88–94. [CrossRef] [PubMed] [Google Scholar]
  3. Bourdenx M, Koulakiotis NS, Sanoudou D, et al. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Prog Neurobiol 2017 ; 155 : 171–193. [CrossRef] [PubMed] [Google Scholar]
  4. Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011 ; 477 : 107–110. [CrossRef] [PubMed] [Google Scholar]
  5. Robustelli P, Piana S, Shaw DE. Developing a molecular dynamics force field for both folded and disordered protein states. Proc Natl Acad Sci U S A 2018 ; 115 : E4758–E4E66. [CrossRef] [PubMed] [Google Scholar]
  6. Schor M, Mey A, MacPhee CE. Analytical methods for structural ensembles and dynamics of intrinsically disordered proteins. Biophys Rev 2016 ; 8 : 429–439. [CrossRef] [PubMed] [Google Scholar]
  7. Raskatov JA, Teplow DB. Using chirality to probe the conformational dynamics and assembly of intrinsically disordered amyloid proteins. Sci Rep 2017 ; 7 : 12433. [CrossRef] [PubMed] [Google Scholar]
  8. Buell AK, Dobson CM, Knowles TP. The physical chemistry of the amyloid phenomenon: thermodynamics and kinetics of filamentous protein aggregation. Essays Biochem 2014 ; 56 : 11–39. [CrossRef] [PubMed] [Google Scholar]
  9. De Giorgi F, Laferriere F, Zinghirino F, et al. Novel self-replicating alpha-synuclein polymorphs that escape ThT monitoring can spontaneously emerge and acutely spread in neurons. Sci Adv 2020; 6. [Google Scholar]
  10. Peelaerts W, Bousset L, Van der Perren A, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015 ; 522 : 340–344. [CrossRef] [PubMed] [Google Scholar]
  11. Dehay B, Bourdenx M, Gorry P, et al. Targeting alpha-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol 2015 ; 14 : 855–866. [CrossRef] [PubMed] [Google Scholar]
  12. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003 ; 24 : 197–211. [CrossRef] [PubMed] [Google Scholar]
  13. Goedert M.. NEURODEGENERATION. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science 2015 ; 349 : 1255555. [CrossRef] [PubMed] [Google Scholar]
  14. Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 2008 ; 14 : 504–506. [CrossRef] [PubMed] [Google Scholar]
  15. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 2008 ; 14 : 501–503. [CrossRef] [PubMed] [Google Scholar]
  16. Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci 2016 ; 17 : 251–260. [CrossRef] [PubMed] [Google Scholar]
  17. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2013 ; 14 : 38–48. [CrossRef] [PubMed] [Google Scholar]
  18. Luk KC, Kehm V, Carroll J, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012 ; 338 : 949–953. [CrossRef] [PubMed] [Google Scholar]
  19. Osterberg VR, Spinelli KJ, Weston LJ, et al. Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep 2015 ; 10 : 1252–1260. [CrossRef] [PubMed] [Google Scholar]
  20. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011 ; 72 : 57–71. [CrossRef] [PubMed] [Google Scholar]
  21. Mougenot AL, Nicot S, Bencsik A, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012 ; 33 : 2225–2228. [CrossRef] [PubMed] [Google Scholar]
  22. Arotcarena ML, Dovero S, Prigent A, et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 2020; 143 : 1462–75. [CrossRef] [PubMed] [Google Scholar]
  23. Bourdenx M, Nioche A, Dovero S, et al. Identification of distinct pathological signatures induced by patient-derived alpha-synuclein structures in nonhuman primates. Sci Adv 2020; 6 : eaaz9165. [CrossRef] [PubMed] [Google Scholar]
  24. Chu Y, Muller S, Tavares A, et al. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain 2019 ; 142 : 3565–3579. [CrossRef] [PubMed] [Google Scholar]
  25. Recasens A, Dehay B, Bove J, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014 ; 75 : 351–362. [CrossRef] [PubMed] [Google Scholar]
  26. Del Tredici K, Rub U, De Vos RA, et al. Where does parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol 2002 ; 61 : 413–426. [CrossRef] [PubMed] [Google Scholar]
  27. Attems J, Jellinger KA. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease. Neuropathol Appl Neurobiol 2008 ; 34 : 466–467. [CrossRef] [PubMed] [Google Scholar]
  28. Zaccai J, Brayne C, McKeith I, et al. Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology 2008 ; 70 : 1042–1048. [CrossRef] [PubMed] [Google Scholar]
  29. Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson’s disease. Mov Disord 2016 ; 31 : 1114–1119. [CrossRef] [PubMed] [Google Scholar]
  30. Surmeier DJ, Obeso JA, Halliday GM. Parkinson’s Disease Is Not Simply a Prion Disorder. J Neurosci 2017 ; 37 : 9799–9807. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.